Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03663283 · ClinicalTrials.gov registry record · Phase 4

Liposomal Bupivacaine Interscalene Nerve Block in Shoulder Arthroplasty

A Phase 4 study, sponsored by Mayo Clinic.

Completed
Registry status
Phase 4
Development phase
104
Enrollment target

NCT03663283: Completed Phase 4 study, sponsored by Mayo Clinic.

NCT03663283 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 104 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03663283, a Phase 4 study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 4
Development phase
104 participants
Enrollment target

Study Summary

The objective of this study is to determine if peripheral nerve block with liposomal bupivacaine in combination with standard bupivacaine will prolong the duration of block, improve pain scores, and decrease opioid utilization in the post-operative period when compared to peripheral nerve block with standard bupivacaine alone.

Primary Outcome

Patient pain scores over the first 72 hours post-operatively as measured by the Visual Analogue Scale where Zero represents no pain and ten represents severe pain.

Interventions

  • DRUG Liposomal Bupivacaine
  • DRUG Bupivacaine Hydrochloride

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2018-10-29
Est. Completion 2020-02-14
Phase Phase 4
Mayo Clinic

2,844 total trials

What the finished NCT03663283 record still lists

NCT03663283 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (80% lower).

The record links to 0 conditions, and to 2 interventions - of which Liposomal Bupivacaine is the first listed.

NCT03663283 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03663283 about?

NCT03663283 is a clinical study titled "Liposomal Bupivacaine Interscalene Nerve Block in Shoulder Arthroplasty". The objective of this study is to determine if peripheral nerve block with liposomal bupivacaine in combination with standard bupivacaine will prolong the duration of block, improve pain scores, and decrease opioid utilization in the post-operative period when compared to peripheral nerve block with...

What is the current status of trial NCT03663283?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 104 participants. The study started on 2018-10-29. Estimated completion is 2020-02-14.

What interventions are being tested in trial NCT03663283?

The interventions under investigation include: Liposomal Bupivacaine (DRUG), Bupivacaine Hydrochloride (DRUG).

Who is sponsoring clinical trial NCT03663283?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03663283's enrollment target sits among peer trials

104 754th of 2000 higher than 1,241 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03403686 · 104 participants

    Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

  • NCT04228367 · 104 participants · NA

    JuggerStitch Post Market Clinical Follow-up Study

  • NCT04268849 · 104 participants · Phase 3

    Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

  • NCT04390724 · 104 participants

    Optimizing Y90 Therapy for Radiation Lobectomy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03663283, the US trial registry maintained by the National Library of Medicine. NCT03663283 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.